The U.S. Food and Drug Administration’s (FDA) Advisory Committee on Immunization Practices (ACIP) met on April 14 to provide its recommendation regarding the pause of the Johnson & Johnson COVID-19 vaccine due to the association of extremely rare but potentially life-threatening blood clots. However, after reviewing the six cases, the ACIP declined to make a recommendation, instead stating that more data was required. The ACIP reported that another meeting will take place sometime in the next 7-10 days to prevent vaccine roll out delays if it is decided the J&J vaccination is safe.
Read more here.
More on: News Regulatory